scispace - formally typeset
F

Fana Alemseged

Researcher at Royal Melbourne Hospital

Publications -  40
Citations -  1315

Fana Alemseged is an academic researcher from Royal Melbourne Hospital. The author has contributed to research in topics: Medicine & Modified Rankin Scale. The author has an hindex of 10, co-authored 23 publications receiving 613 citations. Previous affiliations of Fana Alemseged include University of Melbourne & University of Rome Tor Vergata.

Papers
More filters
Journal ArticleDOI

Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.

Michael D. Hill, +776 more
- 14 Mar 2020 - 
TL;DR: Nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo, and this trial is registered with ClinicalTrials.gov, NCT02930018.
Journal ArticleDOI

Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data

Bruce C.V. Campbell, +267 more
- 13 Jul 2019 - 
TL;DR: Patients with ischaemic stroke 4·5-9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo, and this increase in the rate of symptomatic intracerebral haemorrhage did not negate the overall net benefit of thrombolysis.
Journal ArticleDOI

Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK Part 2 randomized clinical trial

Bruce C.V. Campbell, +63 more
- 07 Apr 2020 - 
TL;DR: Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg of tenecteplase did not significantly improve cerebral reperfusion prior to endovascular thrombectomy, and the findings suggest that the0.40-mg/kg dose ofTenecte Plase does not confer an advantage over the 0.25-mg-kg dose.
Journal ArticleDOI

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Götz Thomalla, +775 more
- 14 Nov 2020 - 
TL;DR: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care despite an increased risk of symptomatic intracranial haemorrhage.